Wellington Management Group
MNPR icon

Wellington Management Group’s Monopar Therapeutics MNPR Stock Holding History

Wellington Management Group’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.7M Sell
158,437
-15,905
-9% -$985K ﹤0.01% 1187
2026
Q1 		$9.55M Sell
174,342
-51,726
-23% -$3.12M ﹤0.01% 1255
2025
Q4 		$14.8M Sell
226,068
-5,395
-2% -$441K ﹤0.01% 1143
2025
Q3 		$18.9M Buy
+231,463
New +$10.3M ﹤0.01% 1048

Other funds holding MNPR

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Wellington Management Group's MNPR Position: Q2 2026 in Review

Wellington Management Group reduced its Monopar Therapeutics (MNPR) stake by 9.1% in Q2 2026, selling an estimated $985K and leaving 158,437 shares worth $14.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1187.

Wellington Management Group first reported a position in MNPR in Q3 2025 and has held it in 4 quarters since. The position peaked at $18.9M in Q3 2025. 96 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

  • Wellington Management Group held 158,437 shares of Monopar Therapeutics worth $14.7M as of Q2 2026.
  • Wellington Management Group sold 15,905 Monopar Therapeutics shares in Q2 2026, an estimated $985K.
  • Monopar Therapeutics made up ﹤0.01% of Wellington Management Group's portfolio in Q2 2026, its #1187 holding.
  • Wellington Management Group first reported a position in Monopar Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Wellington Management Group's Monopar Therapeutics position peaked at $18.9M in Q3 2025.
  • 96 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on Wellington Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.